<DOC>
	<DOCNO>NCT01068145</DOCNO>
	<brief_summary>Trial evaluate dose response SCH 527123 reduce inflammation ozone-induced sputum neutrophilia healthy subject subject COPD .</brief_summary>
	<brief_title>Two-Part Study Evaluate Dose Response SCH 527123 Sputum Neutrophilia Following Ozone Challenge Healthy Subjects Chronic Obstructive Pulmonary Disease ( COPD ) Patients ( P05567 AM7 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Part 1 Subject either sex race age 18 55 year , BMI ( weight [ kg ] /height [ m2 ] ) 19 32 . Subject must FEV1 ≥ 80 % predict value . Subject must nonsmoker ( include cigarette , cigar pip ) exsmoker stop smoke least 6 month ( smoke history ≤ 5 pack year ) . Subject 's clinical laboratory test ( CBC , blood chemistry , urinalysis ) must within normal limit . Subjects must neutrophil count &gt; 2.0 x 109/L . ( also Part 2 ) Subject must free clinically significant disease would interfere study evaluation ( also Part 2 ) . Screening ECG conduction interval must within gender specific normal range ; QTcB males ≤430 msec female ≤450 msec ( also Part 2 ) . Vital sign measurement must : ) oral body temperature , 35.0°C 37.5°C ; b ) systolic blood pressure , 90 140 mm Hg ( 160 mm Hg , Part 2 ) ; c ) diastolic blood pressure , 45 90 mm Hg ( 100 mm Hg , Part 2 ) ; ) pulse rate , 40 100 bpm . Subject partner ( ) must use accepted method contraception trial 2 month posttreatment ( also Part 2 ) . Prior randomization , subject must responder ozone ( also Part 2 ) . Part 2 Subject diagnosis COPD least 1 year FEV1 ≥65 % predict value post bronchodilation ( measurement 30 minute 400 mcg salbutamol administration ) FEV1/FVC &lt; 70 % . Subject either sex race age 40 65 year , BMI 19 32 . Subject must active exsmoker ( cigarette , cigar and/or pipe ) . Subject must normal exercise stress test ( clinically significant ECG finding ) . Part 1 Part 2 Female subject pregnant , intend become pregnant ( within 3 month end study ) , breastfeed . Subject history seasonal perennial allergic rhinitis ( ie , season specific allergen ) . Subject allergy contraindication excipients placebo SCH 527123 formulation salbutamol . Surgical medical condition ( history presence ) might alter ADME drug : ) inflammatory bowel disease , ulcer , gastrointestinal rectal bleeding ; b ) major gastrointestinal tract surgery , ie , gastrectomy , gastroenterostomy , bowel resection ; c ) pancreatic injury pancreatitis ; ) liver disease injury ; e ) impair renal function indicate abnormal creatinine , urinary albumin , BUN/urea clinical significant urinary cellular constituent ( eg , cast ) ; f ) urinary obstruction difficulty void . Subject infectious disease within 4 week prior drug administration . Subject positive hepatitis B surface antigen , hepatitis C antibodies HIV . Subject positive screen drug high potential abuse ( Screening and/or treatment period ) . Subjects history mental instability treat mood disorder . Subject history alcohol drug abuse past 2 year . Subject donate blood past 60 day . Subject demonstrate allergic reaction ( eg , food , drug , atopic reaction asthmatic episode ) may interfere ability participate trial . Subject previously receive SCH 527123 ( Part 2 ) Subject receive follow treatment recently indicate washout period prior Baseline : Parts 1 2 : OTC medication ( exclude paracetamol ) , 14 day . Part 1 : prescription medication , 14 day ; investigational drug , 30 day . Part 2 : vitamin herbal supplement , 14 day ; statin , 4 week ; steroid ( inhale ) , 4 week ; steroid ( oral dermal ) , 8 week ; antibiotic , 6 week ; leukotriene antagonist , 4 week ; NSAIDS , 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>COPD</keyword>
</DOC>